Corticosteroids for dengue - why don't they work?

PLoS Negl Trop Dis. 2013 Dec 12;7(12):e2592. doi: 10.1371/journal.pntd.0002592. eCollection 2013.

Abstract

Background: Dysregulated immune responses may contribute to the clinical complications that occur in some patients with dengue.

Findings: In Vietnamese pediatric dengue cases randomized to early prednisolone therapy, 81 gene-transcripts (0.2% of the 47,231 evaluated) were differentially abundant in whole-blood between high-dose (2 mg/kg) prednisolone and placebo-treated patients two days after commencing therapy. Prominent among the 81 transcripts were those associated with T and NK cell cytolytic functions. Additionally, prednisolone therapy was not associated with changes in plasma cytokine levels.

Conclusion: The inability of prednisolone treatment to markedly attenuate the host immune response is instructive for planning future therapeutic strategies for dengue.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Cytokines / blood
  • Dengue / drug therapy*
  • Female
  • Gene Expression Profiling
  • Humans
  • Immunologic Factors / therapeutic use*
  • Immunomodulation
  • Killer Cells, Natural / immunology
  • Male
  • Placebos / administration & dosage
  • Prednisolone / therapeutic use*
  • T-Lymphocytes, Cytotoxic / immunology
  • Treatment Failure
  • Vietnam
  • Young Adult

Substances

  • Cytokines
  • Immunologic Factors
  • Placebos
  • Prednisolone